Agenus Inc. (AGEN): Price and Financial Metrics


Agenus Inc. (AGEN): $3.23

-0.11 (-3.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 476

in industry

AGEN POWR Grades


  • AGEN scores best on the Value dimension, with a Value rank ahead of 98% of US stocks.
  • The strongest trend for AGEN is in Momentum, which has been heading down over the past 52 weeks.
  • AGEN's current lowest rank is in the Momentum metric (where it is better than 4.19% of US stocks).

AGEN Stock Summary

  • Agenus Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 95.74% of US listed stocks.
  • With a price/earnings ratio of 227.72, Agenus Inc P/E ratio is greater than that of about 97.02% of stocks in our set with positive earnings.
  • As for revenue growth, note that AGEN's revenue has grown 235.5% over the past 12 months; that beats the revenue growth of 96.7% of US companies in our set.
  • Stocks that are quantitatively similar to AGEN, based on their financial statements, market capitalization, and price volatility, are PRTC, SRDX, HLIT, HL, and BSY.
  • Visit AGEN's SEC page to see the company's official filings. To visit the company's web site, go to agenusbio.com.

AGEN Valuation Summary

  • AGEN's price/earnings ratio is -6.4; this is 117.53% lower than that of the median Healthcare stock.
  • Over the past 243 months, AGEN's EV/EBIT ratio has gone down 1.3.
  • Over the past 243 months, AGEN's price/earnings ratio has gone up 2.5.

Below are key valuation metrics over time for AGEN.

Stock Date P/S P/B P/E EV/EBIT
AGEN 2021-08-31 21.0 -5.8 -6.4 -8.8
AGEN 2021-08-30 22.5 -6.3 -6.8 -9.5
AGEN 2021-08-27 21.3 -5.9 -6.5 -9.0
AGEN 2021-08-26 21.5 -6.0 -6.5 -9.1
AGEN 2021-08-25 20.7 -5.7 -6.3 -8.7
AGEN 2021-08-24 21.1 -5.8 -6.4 -8.9

AGEN Growth Metrics

  • Its 4 year cash and equivalents growth rate is now at 17.81%.
  • The 3 year revenue growth rate now stands at 328.89%.
  • Its year over year net cashflow from operations growth rate is now at -13.53%.
AGEN's revenue has moved up $210,154,000 over the prior 15 months.

The table below shows AGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 306.667 -2.518 3.767
2021-06-30 68.545 -165.517 -225.937
2021-03-31 84.76 -147.335 -190.126
2020-12-31 88.17 -139.096 -181.123
2020-09-30 91.405 -135.286 -173.57
2020-06-30 96.513 -131.445 -167.891

AGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AGEN has a Quality Grade of C, ranking ahead of 55.26% of graded US stocks.
  • AGEN's asset turnover comes in at 0.324 -- ranking 139th of 681 Pharmaceutical Products stocks.
  • COCP, MTEM, and LGND are the stocks whose asset turnover ratios are most correlated with AGEN.

The table below shows AGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.324 0.949 8.194
2021-03-31 0.404 0.959 5.948
2020-12-31 0.449 0.973 3.708
2020-09-30 0.504 0.983 2.706
2020-06-30 0.555 0.993 2.612
2020-03-30 0.476 1.000 2.580

AGEN Price Target

For more insight on analysts targets of AGEN, see our AGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.17 (Strong Buy)

AGEN Stock Price Chart Interactive Chart >

Price chart for AGEN

AGEN Price/Volume Stats

Current price $3.23 52-week high $6.79
Prev. close $3.34 52-week low $2.50
Day low $3.20 Volume 2,909,600
Day high $3.41 Avg. volume 4,107,735
50-day MA $4.71 Dividend yield N/A
200-day MA $4.52 Market Cap 829.56M

Agenus Inc. (AGEN) Company Bio


Agenus Inc. engages in discovering and developing innovative treatments for patients with cancer and other diseases. The company was founded in 1994 and is based in Lexington, Massachusetts.


AGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

AGEN Latest Social Stream


Loading social stream, please wait...

View Full AGEN Social Stream

Latest AGEN News From Around the Web

Below are the latest news stories about Agenus Inc that investors may wish to consider to help them evaluate AGEN as an investment opportunity.

Analysts Expect Agenus Inc. (NASDAQ:AGEN) Will Post Earnings of -$0.12 Per Share

Equities research analysts forecast that Agenus Inc. (NASDAQ:AGEN) will announce ($0.12) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Agenus earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.16). Agenus posted earnings of ($0.20) per share in the []

Dakota Financial News | November 15, 2021

Agenus (NASDAQ:AGEN) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Agenus (NASDAQ:AGEN) from a buy rating to a hold rating in a research report report published on Friday morning, Zacks.com reports. According to Zacks, Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic []

Transcript Daily | November 13, 2021

Agenus inc (AGEN) Q3 2021 Earnings Call Transcript

Joining me today are Dr. Garo Armen, Chairman and Chief Executive Officer; Dr. Jennifer Buell, Chief Executive Officer of MiNK Therapeutics; Dr. Steven O'Day, Chief Medical Officer of Agenus; and Christine Klaskin, Vice President of Finance. Now, I will turn the call over to Garo to highlight the progress we have made to-date this year.

Yahoo | November 13, 2021

Agenus Posts Early Data For CTLA-4 Drug Candidate Across Tumor Types

In a Phase I study across nine tumor types, Agenus Incs (NASDAQ: AGEN ) CTLA-4 drug AGN1181 posted one complete response and three partial responses (PRs) as a monotherapy, according to data presented t SITC. The three responders expressed the low-affinity FcRIIIA receptor, Agenus said, which is associated with a lack of response to first-generation CTLA-4 inhibitors. The Phase I study mainly enrolled heavily Full story available on Benzinga.com

Benzinga | November 12, 2021

$57.63 Million in Sales Expected for Agenus Inc. (NASDAQ:AGEN) This Quarter

Wall Street analysts forecast that Agenus Inc. (NASDAQ:AGEN) will announce sales of $57.63 million for the current quarter, according to Zacks. Three analysts have made estimates for Agenus earnings, with the highest sales estimate coming in at $112.90 million and the lowest estimate coming in at $25.00 million. Agenus reported sales of $31.27 million during []

Dakota Financial News | November 12, 2021

Read More 'AGEN' Stories Here

AGEN Price Returns

1-mo -15.89%
3-mo -51.28%
6-mo -23.46%
1-year -12.94%
3-year 40.43%
5-year -25.75%
YTD 1.57%
2020 -21.87%
2019 71.01%
2018 -26.99%
2017 -20.87%
2016 -9.25%

Continue Researching AGEN

Here are a few links from around the web to help you further your research on Agenus Inc's stock as an investment opportunity:

Agenus Inc (AGEN) Stock Price | Nasdaq
Agenus Inc (AGEN) Stock Quote, History and News - Yahoo Finance
Agenus Inc (AGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7843 seconds.